Skip Navigation
Skip to contents

CPP : Cardiovascular Prevention and Pharmacotherapy

Sumissioin : submit your manuscript
SEARCH
Search

Articles

Page Path
HOME > Cardiovasc Prev Pharmacother > Volume 8(3); 2026 > Article
Original Article
Body weight variability and the risk of incident metabolic dysfunction–associated steatotic liver disease (MASLD): a retrospective cohort study from the Kangbuk Samsung Health Study
Eun-Jung Rhee*orcid, Won-Young Lee*orcid
Cardiovascular Prevention and Pharmacotherapy 2026;8(3):69-77.
DOI: https://doi.org/10.36011/cpp.2026.8.e10
Published online: July 28, 2026

Department of Endocrinology and Metabolism, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea

Correspondence to Eun-Jung Rhee, MD Department of Endocrinology and Metabolism, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, 29 Saemunan-ro, Jongno-gu, Seoul 03181, Korea Email: hongsiri@hanmail.net
Won-Young Lee, MD Department of Endocrinology and Metabolism, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, 29 Saemunan-ro, Jongno-gu, Seoul 03181, Korea Email: drlwy@hanmail.net
*Eun-Jung Rhee and Won-Young Lee contributed equally to this study as co-first authors.
• Received: July 3, 2026   • Revised: July 10, 2026   • Accepted: July 13, 2026

Copyright © 2026 Korean Society of Cardio-cerebrovascular Disease Prevention; Korean Society of Cardiovascular Pharmacotherapy.

This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

prev next
  • Background
    Metabolic dysfunction–associated steatotic liver disease (MASLD) is closely associated with obesity, and weight loss remains a cornerstone of its management. However, whether body weight variability—repeated cycles of weight loss and regain—independently predicts MASLD development remains unclear. We examined whether body weight variability across serial health examinations was associated with incident MASLD in healthy adults.
  • Methods
    This study included 1,664 participants from the Kangbuk Samsung Health Study (2007–2019) who underwent at least five serial health examinations and were free of MASLD at the first visit. Body weight variability was quantified as the average successive variability (ASV) of weight across the five visits and categorized into quartiles (Q1–Q4). Incident MASLD was defined as hepatic steatosis on ultrasonography plus at least one cardiometabolic risk factor.
  • Results
    During a median follow-up of 8.9 years (13,897 person-years), 525 participants (31.5%) developed MASLD, corresponding to an incidence rate of 37.8 per 1,000 person-years. MASLD incidence increased across ASV quartiles, from 21.0% in Q1 to 45.5% in Q4. After adjustment for age, sex, baseline body mass index, systolic blood pressure, and fasting glucose, participants in the highest ASV quartile had a higher risk of MASLD than those in the lowest quartile (adjusted hazard ratio [aHR], 1.64; 95% confidence interval [CI], 1.25–2.14). This association persisted after further adjustment for net weight change (aHR, 1.40; 95% CI, 1.06–1.84; P for trend=0.022) and was attenuated but remained directionally consistent after additional adjustment for lifestyle and laboratory factors (aHR, 1.33; 95% CI, 1.00–1.77).
  • Conclusions
    In this exploratory analysis, higher body weight variability was associated with incident MASLD, independent of baseline adiposity and net weight change. These findings suggest that weight stability, rather than repeated weight cycling, may be relevant to MASLD prevention and warrant confirmation in prospective studies.
Metabolic dysfunction–associated steatotic liver disease (MASLD) is the most common chronic liver disease worldwide, affecting an estimated 25% to 30% of adults, and its prevalence continues to rise in parallel with the global epidemics of obesity and type 2 diabetes [1]. Although MASLD was previously regarded as a benign hepatic finding, it is now recognized as a major driver of progressive liver disease, including steatohepatitis, cirrhosis, and hepatocellular carcinoma, and as an independent contributor to cardiovascular and all-cause mortality [2–5].
The nomenclature for fatty liver disease has changed substantially over the past four decades. The original term, nonalcoholic fatty liver disease, described a diagnosis of exclusion based on the absence of significant alcohol intake, viral hepatitis, and steatogenic medication use [6]. In 2020, metabolic dysfunction–associated fatty liver disease reframed the condition around positive metabolic criteria [7]. The 2023 multisociety Delphi consensus subsequently introduced MASLD, which requires hepatic steatosis together with at least one of five cardiometabolic risk factors, thereby defining fatty liver disease as a metabolic liver disorder [8]. This conceptual shift has direct implications for risk stratification, eligibility for emerging pharmacotherapies, and clinical trial inclusion criteria.
Weight loss remains the cornerstone of MASLD management. Even modest reductions in body weight can improve hepatic steatosis and inflammation, whereas weight gain closely tracks the development of hepatic steatosis [9–12]. In real-world settings, however, weight loss is often followed by regain, resulting in repeated cycles of loss and regain commonly referred to as weight cycling [13]. The magnitude of these fluctuations, captured by measures of body weight variability, has been identified as a metabolic risk marker beyond mean body mass index (BMI) [14,15]. Greater body weight variability has been associated with increased risks of cardiovascular events, incident type 2 diabetes, chronic kidney disease, and all-cause mortality, even among individuals who achieve net weight loss [14,16–20].
Despite these observations, few studies have directly examined body weight variability and MASLD development, and their findings have been inconsistent [21,22]. Whether repeated weight fluctuation is associated with incident hepatic steatosis beyond baseline adiposity and net weight change remains uncertain. Therefore, we conducted an exploratory longitudinal analysis within the Kangbuk Samsung Health Study to examine whether greater body weight variability, quantified as the average successive variability (ASV) of weight across five serial health examinations, was associated with MASLD incidence among adults who were free of MASLD at baseline.
Ethics statement
The study protocol was reviewed and approved by the Institutional Review Board of Kangbuk Samsung Hospital (No. KBSMC IRB 2022-12-049). The requirement for informed consent was waived because the analysis used deidentified data obtained during routine health screening. This study was conducted in accordance with the principles of the Declaration of Helsinki and reported in accordance with the STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) guidelines.
Study population and design
This study was a secondary, exploratory analysis of data from the Kangbuk Samsung Health Study, a cohort of Korean adults who underwent comprehensive health examinations at the Total Healthcare Centers of Kangbuk Samsung Hospital between 2007 and 2019 [23,24]. The analytic dataset was originally assembled to investigate serial thyroid function and included 2,291 participants who underwent at least five serial health examinations with repeated thyroid function testing. For the present analysis, participants with MASLD at the first (baseline) visit (n=622) and those with missing data required to compute body weight variability (n=5) were sequentially excluded, yielding a final analytic cohort of 1,664 participants (Fig. 1). Because the cohort was assembled for a different primary purpose, this analysis should be considered exploratory and hypothesis-generating.
Assessment of body weight variability
Body weight was measured to the nearest 0.1 kg by trained staff using standardized, calibrated equipment at each of the five serial examinations; participants wore light indoor clothing and no shoes. Body weight variability was quantified as ASV, defined as the mean absolute difference between consecutive weight measurements across the five visits: ASV=(Σ |W(i+1) − W(i)|) / (k − 1), where W(i) is body weight at visit i and k=5. ASV was prespecified as the sole body weight variability metric for this analysis because it captures the visit-to-visit magnitude of fluctuation independent of the direction or temporal ordering of weight change. Participants missing any of the five weight measurements required to compute ASV (n=5) were excluded, and no imputation was performed. ASV was categorized into quartiles from Q1, the lowest quartile, to Q4, the highest quartile.
Definition of MASLD
Hepatic steatosis was diagnosed by experienced radiologists who were blinded to clinical and laboratory data and who used standard abdominal ultrasonographic criteria [11]: increased hepatic echogenicity, vascular blurring, and deep attenuation of the ultrasound signal. In accordance with the 2023 multisociety consensus definition [8], MASLD was defined as ultrasonographically detected hepatic steatosis together with at least one cardiometabolic risk factor. Using Asian thresholds, the cardiometabolic risk factors were as follows: (1) waist circumference ≥90 cm in men or ≥85 cm in women; (2) fasting glucose ≥100 mg/dL or a diagnosis of type 2 diabetes; (3) systolic blood pressure ≥130 mmHg, diastolic blood pressure ≥85 mmHg, or use of antihypertensive medication; (4) triglycerides ≥150 mg/dL or use of lipid-lowering medication; and (5) high-density lipoprotein cholesterol (HDL-C) <40 mg/dL in men or <50 mg/dL in women, or use of lipid-lowering medication. Incident MASLD was defined as new-onset MASLD after the fifth examination among participants who were free of the condition at the first visit.
Covariates
BMI was calculated as weight in kilograms divided by height in meters squared. Blood pressure, fasting serum glucose, lipid profile components, including triglycerides and HDL-C, and liver enzymes, including alanine aminotransferase (ALT), were measured using standardized protocols in a central laboratory. Smoking status, categorized as never, former, or current smoking, and frequency of alcohol consumption were obtained using standardized questionnaires. All covariates were obtained from the first, or baseline, visit. Habitual physical activity was not included as a covariate because it was missing for a large proportion of participants at baseline.
Statistical analysis
Baseline characteristics are presented as mean±standard deviation for continuous variables and numbers with percentages for categorical variables; they were compared across ASV quartiles using one-way analysis of variance or the chi-square test, as appropriate. Follow-up time was calculated from the fifth examination to the date of incident MASLD or the last examination, and incidence rates were expressed per 1,000 person-years. The cumulative incidence of MASLD across ASV quartiles was estimated using the Kaplan-Meier method and compared using the log-rank test. Multivariable Cox proportional hazards regression was used to estimate adjusted hazard ratios (aHRs) with 95% confidence intervals (CIs), with the lowest ASV quartile (Q1) as the reference. Three sequential models were fitted: model 1 was adjusted for age, sex, baseline BMI, systolic blood pressure, and fasting glucose; model 2 was additionally adjusted for net weight change, defined as fifth-visit weight minus first-visit weight; and model 3 was further adjusted for smoking status, frequency of alcohol consumption, triglycerides, high-density lipoprotein cholesterol, and baseline ALT. The P for trend was obtained by modeling ASV quartile as an ordinal variable. A two-sided P-value of <0.05 was considered statistically significant. Analyses were performed using IBM SPSS ver. 29.0 (IBM Corp).
Baseline characteristics
Among the 1,664 participants (846 men, 50.8%; 818 women, 49.2%; mean age, 38.6±5.3 years), body weight ASV increased progressively across quartiles, from 0.95±0.25 kg in Q1 to 3.76±1.22 kg in Q4 (overall analysis of variance, P<0.001). Baseline characteristics by ASV quartile are shown in Table 1. Participants in higher ASV quartiles were younger and more likely to be male; they also had higher BMI, waist circumference, systolic blood pressure, and ALT levels and lower HDL-C levels, indicating a less favorable baseline cardiometabolic profile with greater weight variability (all P<0.05).
Incidence of MASLD across weight variability quartiles
During a median follow-up of 8.9 years (interquartile range, 8.3–9.8 years; total, 13,897 person-years), 525 participants (31.5%) developed MASLD, corresponding to an incidence rate of 37.8 per 1,000 person-years. MASLD incidence increased monotonically across ASV quartiles: 21.0% (87 of 415) in Q1, 28.0% (118 of 422) in Q2, 32.0% (133 of 416) in Q3, and 45.5% (187 of 411) in Q4 (P for trend <0.001). Kaplan-Meier analysis showed that the cumulative incidence of MASLD increased progressively with greater body weight variability, with clear separation across quartiles (log-rank P<0.001) (Fig. 2).
Association between weight variability and incident MASLD
In model 1, adjusted for age, sex, baseline BMI, systolic blood pressure, and fasting glucose, higher body weight variability was associated with a graded increase in the risk of incident MASLD (Table 2). Compared with Q1, the aHRs were 1.32 (95% CI, 1.00–1.74) for Q2, 1.43 (95% CI, 1.09–1.88) for Q3, and 1.64 (95% CI, 1.25–2.14) for Q4 (Fig. 3). The association remained statistically significant after additional adjustment for net weight change in model 2 (Q4: aHR, 1.40; 95% CI, 1.06–1.84; P for trend=0.022), and net weight change was independently associated with incident MASLD (aHR, 1.11 per kg; 95% CI, 1.09–1.13). After further adjustment for smoking, alcohol consumption, triglycerides, HDL-C, and baseline ALT in model 3, the point estimates were attenuated but remained directionally consistent (Q4: aHR, 1.33; 95% CI, 1.00–1.77). Among the covariates, older age, male sex, and higher baseline BMI were each independently associated with incident MASLD.
In this exploratory analysis of a Korean health screening cohort, greater body weight variability across five serial examinations was associated with a higher risk of incident MASLD in a graded manner. Participants in the highest quartile of weight variability had a 64% higher hazard of developing MASLD than those in the lowest quartile, and this association persisted after adjustment for age, sex, baseline BMI, systolic blood pressure, fasting glucose, and net weight change. Together with previous reports [21,22], these findings add to the limited literature linking body weight variability to fatty liver disease and apply the current MASLD definition to serially measured weight variability [8].
These findings extend previous evidence linking body weight variability to adverse metabolic and cardiovascular outcomes. Large cohort studies and post hoc analyses of clinical trials have reported that greater fluctuation in body weight is associated with increased risks of cardiovascular events, incident diabetes, and mortality, independent of mean body weight [14,16–20]. The present study adds hepatic steatosis to this range of outcomes and suggests that repeated weight cycling may be associated with metabolic stress in the liver. Importantly, the association observed in this study was independent of baseline adiposity, implying that the pattern of weight change over time, not only the absolute level of body weight, may provide prognostic information for MASLD. A previous Korean cohort study reported an association between higher weight variability and nonalcoholic fatty liver disease [21], whereas another study found that weight gain, rather than variability itself, was the principal correlate [22]. By using five serial measurements and the current MASLD definition, the present prospective analysis addresses this question directly while underscoring the importance of accounting for the direction of weight change.
Several biological mechanisms may explain the relationship between weight cycling and hepatic steatosis. Repeated cycles of weight loss and regain are thought to promote preferential accumulation of visceral and ectopic fat during regain phases, along with adverse adipose-tissue remodeling, chronic low-grade inflammation, and progressive impairment of insulin sensitivity [13,25,26]. These processes can increase hepatic lipid delivery and de novo lipogenesis while impairing lipid export, thereby favoring the development of hepatic steatosis [27–29]. Weight cycling may also be accompanied by loss of lean mass and unfavorable shifts in body composition, which may further aggravate insulin resistance [30–33]. These mechanisms provide biological plausibility for a contribution of weight variability to MASLD and are consistent with the graded association observed in this study.
The graded association was attenuated and became borderline after additional adjustment for triglycerides, HDL-C, and ALT in model 3. This attenuation does not necessarily indicate a spurious association; rather, these variables may lie on the pathway between weight variability and hepatic steatosis, and adjustment for such intermediates can result in overadjustment and dilute the estimated association. Because the point estimates remained directionally consistent across all models and the trend persisted after adjustment for net weight change, we regard the demographic-adjusted model and net weight change–adjusted model, models 1 and 2, as the primary analyses and model 3 as a sensitivity analysis.
These findings may be relevant to clinical risk assessment, although they should be interpreted cautiously given the exploratory design. Current guidance for individuals at risk for or living with MASLD emphasizes weight loss [6,10]. Our results raise the possibility that body weight stability, and not only the magnitude of weight loss, may be relevant to MASLD risk. Whether body weight variability adds incremental predictive value beyond established risk factors was not formally evaluated in this study and remains to be determined. Accordingly, any role for weight variability as a clinical risk marker should be considered hypothesis-generating [34].
Strengths and limitations
This study has several strengths. These include its longitudinal design with five serial weight measurements, which allowed body weight variability to be quantified with greater precision than in the two-point assessments used in most previous studies; the exclusion of prevalent MASLD at baseline, which reduced the potential for reverse causation; the use of standardized health screening protocols and a central laboratory; and sequential adjustment for net weight change and for lifestyle and laboratory factors. Several limitations should also be acknowledged. First, and most importantly, this was a secondary, exploratory analysis of a cohort originally assembled for serial thyroid function testing; the exposure and analytic approach were defined after the cohort had been formed, and the findings should therefore be regarded as hypothesis-generating and confirmed in prospectively designed studies. Second, because participants were selected on the basis of repeated thyroid function testing and were relatively young, health-conscious Korean adults, generalizability may be limited and residual selection effects cannot be excluded. Third, hepatic steatosis was assessed by ultrasonography, which is less sensitive than magnetic resonance imaging–based proton density fat fraction or liver biopsy for detecting and quantifying mild steatosis [6]. Fourth, intentional and unintentional weight change could not be distinguished, and habitual physical activity could not be included because of extensive missing data; therefore, residual confounding cannot be excluded. Finally, because this was an observational study, the findings demonstrate association rather than causation.
Conclusions
This exploratory analysis of a Korean health screening cohort found that higher body weight variability was associated with an increased risk of incident MASLD, and this association persisted after adjustment for baseline adiposity and net weight change. These findings suggest that weight stability, rather than repeated cycles of weight loss and regain, may be relevant to MASLD prevention. Given the secondary and exploratory nature of the analysis, these results should be confirmed in prospectively designed studies, and their mechanisms should be investigated further.

Author contributions

Conceptualization: all authors; Data curation: EJR; Formal analysis: EJR; Investigation: EJR; Methodology: all authors; Supervision: WYL; Writing–original draft: EJR; Writing–review & editing: all authors. All authors read and approved the final manuscript.

Conflicts of interest

The authors have no conflicts of interest to declare.

Funding

The authors received no financial support for this study.

Acknowledgments

The authors used Claude (Anthropic) for manuscript drafting, language editing, and journal-style formatting; and SciSpace (Pubgenius Inc) for reference cross-checking. Artificial intelligence was not used for the study design, data analysis, or interpretation. The authors verified all content and references and take full responsibility for the work.

Fig. 1.
Study flow diagram. ASV, average successive variability; MASLD, metabolic dysfunction–associated steatotic liver disease.
cpp-2026-8-e10f1.jpg
Fig. 2.
Cumulative incidence of metabolic dysfunction–associated steatotic liver disease (MASLD) during follow-up, stratified by quartile of body weight variability, quantified as the average successive variability (ASV). The cumulative incidence increased progressively from Q1 (lowest) to Q4 (highest) (log-rank P<0.001).
cpp-2026-8-e10f2.jpg
Fig. 3.
Adjusted hazard ratios (aHRs) and 95% confidence intervals (CIs) for incident metabolic dysfunction–associated steatotic liver disease (MASLD) by quartile of body weight variability, quantified as the average successive variability (ASV). Model 1 used Q1 as the reference and was adjusted for age, sex, baseline body mass index, systolic blood pressure, and fasting glucose. *P<0.05.
cpp-2026-8-e10f3.jpg
Table 1.
Baseline characteristics of study participants by quartile of body weight variability
Characteristic ASV quartile P-value
Q1 (n=415) Q2 (n=422) Q3 (n=416) Q4 (n=411)
Age (yr) 39.7±5.2 38.9±5.5 38.0±4.8 37.7±5.6 <0.001
Male sex 184 (44.3) 210 (49.8) 229 (55.0) 223 (54.3) 0.007
Body mass index (kg/m²) 21.7±2.6 22.1±2.5 22.5±2.4 23.6±2.8 <0.001
Waist circumference (cm)a) 76.0±7.5 77.7±7.3 79.1±7.3 81.0±7.5 <0.001
Body weight ASV (kg) 0.95±0.25 1.57±0.15 2.22±0.25 3.76±1.22 <0.001
Systolic blood pressure (mmHg) 110.2±12.2 111.5±12.0 112.0±12.1 113.1±12.4 0.008
HDL-C level (mg/dL) 59.0±13.1 57.2±13.4 56.9±13.5 56.4±12.6 0.024
ALT level (IU/L) 17.9±9.9 19.3±11.3 20.0±11.2 21.2±15.5 0.001

Values are presented as mean±standard deviation or number (%). P-values were derived from one-way analysis of variance for continuous variables and the chi-square test for categorical variables.

ALT, alanine aminotransferase; ASV, average successive variability; HDL-C, high-density lipoprotein cholesterol.

a)Waist circumference was available for 737 participants.

Table 2.
Association between body weight variability and incident MASLD
ASV quartile No. of events Incidence (%) aHR (95% CI)
Model 1 Model 2 Model 3
Q1 (n=415) 87 21.0 1 (Reference) 1 (Reference) 1 (Reference)
Q2 (n=422) 118 28.0 1.32 (1.00–1.74) 1.27 (0.96–1.68) 1.06 (0.79–1.43)
Q3 (n=416) 133 32.0 1.43 (1.09–1.88) 1.36 (1.03–1.79) 1.18 (0.89–1.58)
Q4 (n=411) 187 45.5 1.64 (1.25–2.14) 1.40 (1.06–1.84) 1.33 (1.00–1.77)

ASV was categorized into quartiles from Q1 (lowest) to Q4 (highest). Incidence is the cumulative proportion developing MASLD during follow-up. Over 13,897 person-years, the overall incidence rate was 37.8 per 1,000 person-years. Model 1 was adjusted for age, sex, baseline body mass index, systolic blood pressure, and fasting glucose. Model 2 was adjusted for model 1 covariates plus net weight change (fifth-visit weight minus first-visit weight). Model 3 (sensitivity analysis) was adjusted for model 2 covariates plus smoking status, frequency of alcohol consumption, triglycerides, high-density lipoprotein cholesterol, and baseline alanine aminotransferase. In model 2, net weight change was independently associated with incident MASLD (aHR, 1.11 per kg; 95% CI, 1.09–1.13; P for trend=0.022).

aHR, adjusted hazard ratio; ASV, average successive variability; CI, confidence interval; MASLD, metabolic dysfunction–associated steatotic liver disease.

  • 1. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease: meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016;64:73–84. ArticlePubMedPMC
  • 2. Powell EE, Wong VW, Rinella M. Non-alcoholic fatty liver disease. Lancet 2021;397:2212–24. ArticlePubMedPMC
  • 3. Targher G, Byrne CD, Tilg H. MASLD: a systemic metabolic disorder with cardiovascular and malignant complications. Gut 2024;73:691–702. ArticlePubMedPMC
  • 4. Byrne CD, Targher G. NAFLD: a multisystem disease. J Hepatol 2015;62(1 Suppl):S47–64. ArticlePubMed
  • 5. Stefan N, Cusi K. A global view of the interplay between non-alcoholic fatty liver disease and diabetes. Lancet Diabetes Endocrinol 2022;10:284–96. ArticlePubMedPMC
  • 6. Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology 2018;67:328–57. ArticlePubMedPMCPDF
  • 7. Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol 2020;73:202–9. ArticlePubMed
  • 8. Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology 2023;78:1966–86. ArticlePubMedPMC
  • 9. Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, Torres-Gonzalez A, Gra-Oramas B, Gonzalez-Fabian L, et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology 2015;149:367–78. ArticlePubMedPMC
  • 10. Romero-Gómez M, Zelber-Sagi S, Trenell M. Treatment of NAFLD with diet, physical activity and exercise. J Hepatol 2017;67:829–46. ArticlePubMedPMC
  • 11. Chang Y, Ryu S, Sung E, Woo HY, Cho SI, Yoo SH, et al. Weight gain within the normal weight range predicts ultrasonographically detected fatty liver in healthy Korean men. Gut 2009;58:1419–25. ArticlePubMed
  • 12. Sung KC, Wild SH, Byrne CD. Resolution of fatty liver and risk of incident diabetes. J Clin Endocrinol Metab 2013;98:3637–43. ArticlePubMedPDF
  • 13. Montani JP, Schutz Y, Dulloo AG. Dieting and weight cycling as risk factors for cardiometabolic diseases: who is really at risk? Obes Rev 2015;16 Suppl 1:7–18. ArticlePubMed
  • 14. Bangalore S, Fayyad R, Laskey R, DeMicco DA, Messerli FH, Waters DD. Body-weight fluctuations and outcomes in coronary disease. N Engl J Med 2017;376:1332–40. ArticlePubMed
  • 15. Rhee EJ. Weight cycling and its cardiometabolic impact. J Obes Metab Syndr 2017;26:237–42. ArticlePubMedPMC
  • 16. Zou H, Yin P, Liu L, Liu W, Zhang Z, Yang Y, et al. Body-weight fluctuation was associated with increased risk for cardiovascular disease, all-cause and cardiovascular mortality: a systematic review and meta-analysis. Front Endocrinol (Lausanne) 2019;10:728.ArticlePubMedPMC
  • 17. Oh TJ, Moon JH, Choi SH, Lim S, Park KS, Cho NH, et al. Body-weight fluctuation and incident diabetes mellitus, cardiovascular disease, and mortality: a 16-year prospective cohort study. J Clin Endocrinol Metab 2019;104:639–46. ArticlePubMedPDF
  • 18. Kim MK, Han K, Park YM, Kwon HS, Kang G, Yoon KH, et al. Associations of variability in blood pressure, glucose and cholesterol concentrations, and body mass index with mortality and cardiovascular outcomes in the general population. Circulation 2018;138:2627–37. ArticlePubMed
  • 19. Nam GE, Kim W, Han K, Lee CW, Kwon Y, Han B, et al. Body weight variability and the risk of cardiovascular outcomes and mortality in patients with type 2 diabetes: a nationwide cohort study. Diabetes Care 2020;43:2234–41. ArticlePubMedPDF
  • 20. Camoin M, Mohammedi K, Saulnier PJ, Hadjadj S, Gautier JF, Riveline JP, et al. Body-weight cycling and risk of diabetic kidney disease in people with type 1 diabetes in the DCCT/EDIC population. J Clin Endocrinol Metab 2025;110:e3334–42. ArticlePubMedPDF
  • 21. Jung I, Koo DJ, Lee MY, Moon SJ, Kwon H, Park SE, et al. Increased risk of nonalcoholic fatty liver disease in individuals with high weight variability. Endocrinol Metab (Seoul) 2021;36:845–54. ArticlePubMedPMCPDF
  • 22. Cho EJ, Yu SJ, Jung GC, Kwak MS, Yang JI, Yim JY, et al. Body weight gain rather than body weight variability associated with increased risk of nonalcoholic fatty liver disease. Sci Rep 2021;11:14428.ArticlePubMedPMC
  • 23. Ryu S, Chang Y, Kim DI, Kim WS, Suh BS. γ-Glutamyltransferase as a predictor of chronic kidney disease in nonhypertensive and nondiabetic Korean men. Clin Chem 2007;53:71–7. ArticlePubMedPDF
  • 24. Rhee EJ, Kim MK, Park SE, Park CY, Baek KH, Lee WY, et al. High serum vitamin D levels reduce the risk for nonalcoholic fatty liver disease in healthy men independent of metabolic syndrome. Endocr J 2013;60:743–52. ArticlePubMed
  • 25. Dulloo AG, Jacquet J, Montani JP, Schutz Y. How dieting makes the lean fatter: from a perspective of body composition autoregulation through adipostats and proteinstats awaiting discovery. Obes Rev 2015;16 Suppl 1:25–35. ArticlePubMed
  • 26. Speakman JR, Levitsky DA, Allison DB, Bray MS, de Castro JM, Clegg DJ, et al. Set points, settling points and some alternative models: theoretical options to understand how genes and environments combine to regulate body adiposity. Dis Model Mech 2011;4:733–45. ArticlePubMedPMC
  • 27. Loomba R, Friedman SL, Shulman GI. Mechanisms and disease consequences of nonalcoholic fatty liver disease. Cell 2021;184:2537–64. ArticlePubMedPMC
  • 28. Fabbrini E, Sullivan S, Klein S. Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology 2010;51:679–89. ArticlePubMedPMC
  • 29. Petersen MC, Shulman GI. Mechanisms of insulin action and Insulin resistance. Physiol Rev 2018;98:2133–223. ArticlePubMedPMC
  • 30. Rossi AP, Rubele S, Calugi S, Caliari C, Pedelini F, Soave F, et al. Weight cycling as a risk factor for low muscle mass and strength in a population of males and females with obesity. Obesity (Silver Spring) 2019;27:1068–75. ArticlePubMedPDF
  • 31. Rhee EJ, Lee WY, Cho YK, Kim BI, Sung KC. Hyperinsulinemia and the development of nonalcoholic fatty liver disease in nondiabetic adults. Am J Med 2011;124:69–76. ArticlePubMed
  • 32. Bosy-Westphal A, Schautz B, Lagerpusch M, Pourhassan M, Braun W, Goele K, et al. Effect of weight loss and regain on adipose tissue distribution, composition of lean mass and resting energy expenditure in young overweight and obese adults. Int J Obes (Lond) 2013;37:1371–7. ArticlePubMedPDF
  • 33. Lee JS, Visser M, Tylavsky FA, Kritchevsky SB, Schwartz AV, Sahyoun N, et al. Weight loss and regain and effects on body composition: the Health, Aging, and Body Composition Study. J Gerontol A Biol Sci Med Sci 2010;65:78–83. ArticlePubMedPMC
  • 34. European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol 2024;81:492–542. ArticlePubMedPMCPDF

Figure & Data

References

    Citations

    Citations to this article as recorded by  
    • Durability, not just magnitude: weight stability and the risk of metabolic dysfunction–associated steatotic liver disease (MASLD)
      Seo-Yeon Gwak
      Cardiovascular Prevention and Pharmacotherapy.2026; 8(3): 78.     CrossRef

    Figure
    • 0
    • 1
    • 2
    Related articles
    Body weight variability and the risk of incident metabolic dysfunction–associated steatotic liver disease (MASLD): a retrospective cohort study from the Kangbuk Samsung Health Study
    Image Image Image
    Fig. 1. Study flow diagram. ASV, average successive variability; MASLD, metabolic dysfunction–associated steatotic liver disease.
    Fig. 2. Cumulative incidence of metabolic dysfunction–associated steatotic liver disease (MASLD) during follow-up, stratified by quartile of body weight variability, quantified as the average successive variability (ASV). The cumulative incidence increased progressively from Q1 (lowest) to Q4 (highest) (log-rank P<0.001).
    Fig. 3. Adjusted hazard ratios (aHRs) and 95% confidence intervals (CIs) for incident metabolic dysfunction–associated steatotic liver disease (MASLD) by quartile of body weight variability, quantified as the average successive variability (ASV). Model 1 used Q1 as the reference and was adjusted for age, sex, baseline body mass index, systolic blood pressure, and fasting glucose. *P<0.05.
    Body weight variability and the risk of incident metabolic dysfunction–associated steatotic liver disease (MASLD): a retrospective cohort study from the Kangbuk Samsung Health Study
    Characteristic ASV quartile P-value
    Q1 (n=415) Q2 (n=422) Q3 (n=416) Q4 (n=411)
    Age (yr) 39.7±5.2 38.9±5.5 38.0±4.8 37.7±5.6 <0.001
    Male sex 184 (44.3) 210 (49.8) 229 (55.0) 223 (54.3) 0.007
    Body mass index (kg/m²) 21.7±2.6 22.1±2.5 22.5±2.4 23.6±2.8 <0.001
    Waist circumference (cm)a) 76.0±7.5 77.7±7.3 79.1±7.3 81.0±7.5 <0.001
    Body weight ASV (kg) 0.95±0.25 1.57±0.15 2.22±0.25 3.76±1.22 <0.001
    Systolic blood pressure (mmHg) 110.2±12.2 111.5±12.0 112.0±12.1 113.1±12.4 0.008
    HDL-C level (mg/dL) 59.0±13.1 57.2±13.4 56.9±13.5 56.4±12.6 0.024
    ALT level (IU/L) 17.9±9.9 19.3±11.3 20.0±11.2 21.2±15.5 0.001
    ASV quartile No. of events Incidence (%) aHR (95% CI)
    Model 1 Model 2 Model 3
    Q1 (n=415) 87 21.0 1 (Reference) 1 (Reference) 1 (Reference)
    Q2 (n=422) 118 28.0 1.32 (1.00–1.74) 1.27 (0.96–1.68) 1.06 (0.79–1.43)
    Q3 (n=416) 133 32.0 1.43 (1.09–1.88) 1.36 (1.03–1.79) 1.18 (0.89–1.58)
    Q4 (n=411) 187 45.5 1.64 (1.25–2.14) 1.40 (1.06–1.84) 1.33 (1.00–1.77)
    Table 1. Baseline characteristics of study participants by quartile of body weight variability

    Values are presented as mean±standard deviation or number (%). P-values were derived from one-way analysis of variance for continuous variables and the chi-square test for categorical variables.

    ALT, alanine aminotransferase; ASV, average successive variability; HDL-C, high-density lipoprotein cholesterol.

    a)Waist circumference was available for 737 participants.

    Table 2. Association between body weight variability and incident MASLD

    ASV was categorized into quartiles from Q1 (lowest) to Q4 (highest). Incidence is the cumulative proportion developing MASLD during follow-up. Over 13,897 person-years, the overall incidence rate was 37.8 per 1,000 person-years. Model 1 was adjusted for age, sex, baseline body mass index, systolic blood pressure, and fasting glucose. Model 2 was adjusted for model 1 covariates plus net weight change (fifth-visit weight minus first-visit weight). Model 3 (sensitivity analysis) was adjusted for model 2 covariates plus smoking status, frequency of alcohol consumption, triglycerides, high-density lipoprotein cholesterol, and baseline alanine aminotransferase. In model 2, net weight change was independently associated with incident MASLD (aHR, 1.11 per kg; 95% CI, 1.09–1.13; P for trend=0.022).

    aHR, adjusted hazard ratio; ASV, average successive variability; CI, confidence interval; MASLD, metabolic dysfunction–associated steatotic liver disease.


    CPP : Cardiovascular Prevention and Pharmacotherapy
    TOP